Latest News and Press Releases

Approval of new 60mg dose expands current indication to include long-term treatment beyond the first year AstraZeneca today announced that the European Commission has granted marketing authorisation...

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for ZurampicTM(lesinurad) 200mg in combination with a xanthine oxidase inhibitor (XOI) for the...

DURVALUMAB granted Breakthrough Therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer AstraZeneca and MedImmune, its global biologics research and...

AstraZeneca PLC Listing Rule LR 9.6.14 R (2) On 16 February 2016, Leif Johansson, Non-Executive Chairman of AstraZeneca PLC, was elected as a new member to the Board of Directors of Autoliv, Inc. A...

4 February 2016 Full-Year and Q4 2015 Results Financial Summary +---------------------+------+----+------++-----+----+------+ | |FY 2015 ||Q4 2015 ...

AstraZeneca PLC Full-Year and Q4 Results 2015  On Thursday, 4 February 2016, AstraZeneca PLC will release its full-year and Q4 2015 results at 07:00 GMT.  A presentation will take place at 12:00...

 TAGRISSO™ (osimertinib) approved in EU as first-in-class treatment for PATIENTS WITH EGFR T790M mutation-positive metastatic non-small cell lung cancer TAGRISSO™ is the first new medicine to be...

ASTRAZENECA COMPLETES TRANSACTION FOR MAJORITY EQUITY STAKE INVESTMENT IN ACERTA PHARMA AstraZeneca today announced that it has completed the transaction to acquire a majority equity stake in Acerta...

LYNPARZA™ (Olaparib) granted Breakthrough Therapy Designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer AstraZeneca today announced that...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 31 December 2015, Cori Bargmann, a Director of the Company notified us that, on 30 December 2015, she became...